×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy
Maurie Markman, M.D.
When I began my medical oncology career more than 30 years ago, I was determined to be among the first generation of researchers to cure cancer.
Brielle Benyon
Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.
Jessica Skarzynski
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
Brielle Benyon
Next-generation sequencing and personalized approaches will continue to improve cancer outcomes. But there’s still much work to be done.
Brielle Benyon
An expert discusses the current landscape – as well as future prospects – for immunotherapy in lung cancer.
Beth Fand Incollingo
Immunotherapy has become a buzzword in the cancer community, but to Sean Parker it’s much more. The 39-year-old billionaire is intensely focused on the promise of immunotherapy, and has become a major force in helping to drive its potential to cure cancers.
Beth Fand Incollingo
A retrospective study found that clinical trials may have fewer reported side effects than the real world.
Jessica Skarzynski and Kristie L. Kahl
While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.
Katie Kosko
Although immunotherapies show promise for patients, there are still challenges ahead.
Brielle Urciuoli
Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.